Results 211 to 220 of about 109,910 (290)

Comparative Study on Burden, Features and Determinants of Disorders of Gut‐Brain Interaction Between Southern Europe and the Rest of Continent: Results From the Rome Foundation Global Epidemiology Study

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background and Aim Disorders of gut–brain interaction (DGBI) are highly prevalent worldwide. Although the epidemiology of DGBIs in Europe has been previously investigated, data comparing disease prevalence across European regions in relation to sociodemographic and lifestyle factors are lacking.
Giovanni Marasco   +6 more
wiley   +1 more source

Early‐life Giardia infection and behavioural dysregulation in two dogs: A case‐based exploration of the gut microbiome–brain axis

open access: yesVeterinary Record Case Reports, Volume 14, Issue 2, May 2026.
Abstract This case report describes two dogs exhibiting severe behavioural problems, both diagnosed with early‐life giardiasis and raised in environments lacking adequate maternal care and socialisation. Both dogs experienced chronic gastrointestinal and dermatological issues, as well as prolonged early‐life stress, which likely contributed to ...
Daniëlle Hartman   +3 more
wiley   +1 more source

Enteric Nervous System Damage by Food Contaminants: A Pathway to Neurodegeneration?

open access: yesComprehensive Reviews in Food Science and Food Safety, Volume 25, Issue 3, May 2026.
ABSTRACT The enteric nervous system (ENS), a key component of the gut–brain axis, has emerged as a critical player in the pathogenesis of Parkinson's disease (PD). It is the first neural system exposed to food contaminants (FCs)—a diverse group of ubiquitous toxic compounds fortuitously present in food derived from production, processing, storage, or ...
Helena Ramos   +3 more
wiley   +1 more source

The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient‐as‐Own‐Control Designs

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT A frequently cited concern regarding patient‐as‐own‐control trial designs in rare disease is the potential for placebo and related effects to inflate apparent treatment efficacy. Whether this concern is disqualifying or manageable has not been systematically evaluated.
Marshall L. Summar, Janet Woodcock
wiley   +1 more source

A Scoping Review of Non‐Opioid Therapeutics for Opioid Withdrawal: Translational Relevance to Neonatal Opioid Withdrawal Syndrome (NOWS) Research

open access: yesClinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT In the wake of the ongoing opioid epidemic, the incidence of neonatal opioid withdrawal syndrome (NOWS) has surged. While the short‐term effects of NOWS are well‐characterized, long‐term physiological and molecular consequences remain unclear.
Sara L. Mills‐Huffnagle   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy